Bio-Rad LaboratoriesFRA:BUWA +3.27%72 FCF Margin % is 13.19% as of Mar. 2026, which is 42% above its 10-year median of 9.27. GuruFocus rates FRA:BUWA with a GF Score™ of 72/100 and a GF Value™ of €272.83 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 82.21% on this metric.
The historical rank and industry rank for Bio-Rad Laboratories's FCF Margin % or its related term are showing as below:
FRA:BUWA'
s FCF Margin % Range Over the Past 10 Years
Min: -0.51 Med: 9.27 Max: 18.71
Current: 13.78
During the past 13 years, the highest FCF Margin % of Bio-Rad Laboratories was 18.71%. The lowest was -0.51%. And the median was 9.27%.
FRA:BUWA's FCF Margin % is ranked better than 82.21% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs FRA:BUWA: 13.78
Bio-Rad Laboratories FCF Margin % Related Terms
Bio-Rad Laboratories FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BUWA vs BRKR, MASI, PODD: FCF Margin % Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (FRA:BUWA) has a FCF Margin % of 13.19% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio-Rad Laboratories and its competitors. This is 42% above median its historical median of 9.27. According to the industry distribution chart, Bio-Rad Laboratories ranks #145 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 17.8%.
Is Bio-Rad Laboratories' FCF Margin % too high?
Bio-Rad Laboratories' current FCF Margin % of 13.19% is 42% above median its 10-year median of 9.27. Based on the distribution chart, Bio-Rad Laboratories ranks #145 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' FCF Margin % compare to BRKR and MASI?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #145 out of 815 companies for FCF Margin %. This places Bio-Rad Laboratories in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current FCF Margin % is 13.19%, which is 42% above median its own 10-year median of 9.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Undervalued. The stock's GF Value™ is €272.83, compared to a current price of €246.00 — trading 9.8% below its estimated fair value. The current FCF Margin % is 13.19%, which is 42% above median its 10-year median of 9.27. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current FCF Margin % is 13.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of €246.00 is trading 9.8% below its estimated GF Value™ of €272.83.
GuruFocus considers Bio-Rad Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:BUWA:
FCF Margin %: 13.19% (42% above median its 10-year median of 9.27)
GF Value™: €272.83 vs. price of €246.00 (9.8% below fair value)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score
Get the complete analysis for FRA:BUWA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
